Bookmark
Forward
QuickView for Neostigmine (compound)
PubChem
| Name: | Neostigmine |
|---|---|
| PubChem Compound ID: | 4456 |
| Description: | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier. |
| Molecular formula: | C12H19N2O2+ |
| Molecular weight: | 223.292 g/mol |
| Synonyms: |
114-80-7; Prostigmine; NCGC00015730-02; NINDS_000198; NCGC00015730-01; Spectrum_001061; DivK1c_000165; Neostigminum; KBio2_001541; KBio1_000198.
show more » |
DrugBank
Identification
| Name: | Neostigmine |
|---|---|
| Name (isomeric): | DB01400 |
| Drug Type: | small molecule |
| Description: | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier. |
| Brand: | Prostigmin, Neostigmine omega |
| Category: | Parasympathomimetics, Cholinesterase Inhibitors |
| CAS number: | 59-99-4 |
Pharmacology
| Indication: | Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone. |
|---|---|
| Pharmacology: |
Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it c...
show more » |
| Mechanism of Action: |
Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both...
show more » |
| Absorption: | Neostigmine bromide is poorly absorbed from the gastrointestinal tract following oral administration |
| Protein binding: | Protein binding to human serum albumin ranges from 15 to 25 percent. |
| Biotransformation: | Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver. |
| Half Life: | The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes. |
| Toxicity: | Overdosage of Neostigmine can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. The LD 50 of neostigmine methylsulfate in mice is 0.3 ± 0.02 mg/kg intravenously, 0.54 ± 0.03 mg/kg subcutaneously, and 0.395 ± 0.025 mg/kg intramuscularly; in rats the LD 50 is 0.315 ± 0.019 mg/kg intravenously, 0.445 ± 0.032 mg/kg subcutaneously, and 0.423 ± 0.032 mg/kg intramuscularly. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
Transporters
